November 27, 2024
“For too long, the management of psoriasis and other immune-mediated inflammatory diseases has suffered from an acceptance that improvement rather than cure is good enough. Our […]
November 26, 2024
TOPLINE: Lichen planus (LP) affects an estimated 0.15% of US adults, and more than half of patients do not receive treatment within a year of diagnosis […]
November 25, 2024
Recently published consensus guidelines for low-dose oral minoxidil (LDOM) treatment of hair loss provide best-practice recommendations in areas ranging from pretreatment considerations and counseling to patient […]
November 22, 2024
LAS VEGAS — When patients with rosacea consult Julie C. Harper, MD, about persistent facial erythema, she often recommends brimonidine 0.33% gel or oxymetazoline 1% cream. […]
November 22, 2024
Nearly every medication comes with side effects, and in cancer therapies, they can be severe. Clinicians must often weigh the benefits of treatment against potential adverse […]
November 20, 2024
The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the treatment of adults with moderate to severe hidradenitis […]
November 20, 2024
A population-based study has shown a slightly elevated risk for patients’ developing skin disorders, including alopecia areata (AA), alopecia totalis (AT), vitiligo, and bullous pemphigoid (BP), […]
November 20, 2024
TOPLINE: MEK inhibitors are frequently associated with cutaneous adverse events in pediatric patients, and binimetinib was associated with more severe reactions than selumetinib in a retrospective […]
November 19, 2024
The addition of dupilumab significantly reduced itching and hives compared with placebo in patients with chronic spontaneous urticaria (CSU) that was uncontrolled with H1-antihistamines, based on […]